ReAlta Life Sciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients with Steroid-Refractory Acute Graft-versus-Host Disease
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT06343792
- Locations
- 🇺🇸
Site 0191, Duarte, California, United States
🇺🇸Site 1343, Los Angeles, California, United States
🇺🇸Site 1318, Atlanta, Georgia, United States
Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Phase 2
Active, not recruiting
- Conditions
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06175065
- Locations
- 🇺🇸
Site 02, Saint Petersburg, Florida, United States
🇺🇸Site 03, Glen Burnie, Maryland, United States
🇺🇸Site 04, Omaha, Nebraska, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05778188
- Locations
- 🇺🇸
Study Site 020, San Diego, California, United States
🇺🇸Study Site 019, San Diego, California, United States
🇺🇸Study Site 018, Miami, Florida, United States
A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPS
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)Drug: RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses)Drug: Placebo (saline dosed every 8 hours for a total of 3 doses)
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05351671
- Locations
- 🇩🇪
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany
A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05298787
- Locations
- 🇨🇦
Altasciences, Montreal, Quebec, Canada
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
Phase 1
Withdrawn
- Conditions
- ALICOVID-19Acute Lung Injury
- Interventions
- Drug: RLS-0071 10 mg/kgDrug: RLS-0071 40 mg/kgDrug: Placebo
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- ReAlta Life Sciences, Inc.
- Registration Number
- NCT04574869
- Locations
- 🇺🇸
Henry Ford Health Systems, Detroit, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath